2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07G.05 Maximum Standardized Uptake Value and Cell-Free DNA to Predict Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer

EP.07G.05 Maximum Standardized Uptake Value and Cell-Free DNA to Predict Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study explores the potential of maximum standardized uptake value (maxSUV) from PET/CT scans and circulating cell-free DNA (cfDNA) levels as predictive tools for determining the necessity of adjuvant chemotherapy (ACT) in patients with resectable non-small cell lung cancer (NSCLC). Conducted at Cruces University Hospital in Spain, the prospective cohort study included 90 patients undergoing surgery for early-stage NSCLC. <br /><br />The researchers aimed to see whether combining traditional clinical factors with these novel biomarkers could improve decision-making for ACT, which is typically recommended post-surgery but not universally beneficial. Patients’ data, including age, sex, smoking habits, cancer stage, surgical type, and whether they received ACT, were collected, alongside the maxSUV and cfDNA concentration measurements.<br /><br />Key findings showed no correlation between cfDNA concentration and maxSUV. Logistic regression models incorporating both these variables slightly improved the prediction of ACT necessity, with the most accurate model demonstrating 80% accuracy, 79% sensitivity, and 81% specificity. This suggests a moderate predictive capacity, indicating that while these biomarkers do not independently dictate treatment decisions, they could complement existing clinical parameters to tailor adjuvant therapies more effectively.<br /><br />The study concludes that combining molecular biomarkers like cfDNA and maxSUV with clinical data offers a promising approach for precision medicine in NSCLC. While these models show potential, continued research integrating various novel biomarkers with clinical variables is necessary for optimizing therapeutic strategies, paving the way for more personalized treatment regimens post-surgery. This aligns with broader trends in oncology where molecular biology advancements increasingly support targeted therapy selections.

Asset Subtitle

Eider Azkona Uribelarrea

Meta Tag

Speaker Eider Azkona Uribelarrea

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

maximum standardized uptake value

PET/CT scans

circulating cell-free DNA

adjuvant chemotherapy

non-small cell lung cancer

biomarkers

precision medicine

logistic regression

Cruces University Hospital

predictive tools